India Approves Stempeutics Knee Osteoarthritis Stem Cell Therapy
Analysis based on 9 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026
The approval and clinical launch of an indigenous stem cell therapy for knee osteoarthritis opens a new regulated regenerative medicine segment in India, potentially benefiting Cipla and Stempeutics Research through first-mover advantage in a large patient pool. Market impact is likely limited in the near term given the niche indication and early-stage rollout, but it signals growing commercial viability of cell-based therapies in the Indian pharmaceutical market.
India's India — Drugs Controller General of India (DCGI) has approved an allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis, marking the first time such an approved regenerative therapy enters clinical practice in the country. The therapy is manufactured by Stempeutics Research and made available by Cipla. It is being administered for the first time in Tamil Nadu at Dr. Kamakshi Memorial Hospitals in Chennai, where orthopedic surgeon Dr. Deepak Kumar KS and Dr. Sathish Kumar Thangamani, a consultant at the hospital and Senior Assistant Professor at Meharry Medical College, collaborated to deliver the treatment to carefully selected patients with Grade II and III knee osteoarthritis. The therapy is designed to leverage the anti-inflammatory, immunomodulatory and cartilage-protective potential of mesenchymal stem cells, offering a potential option between conservative care and knee replacement surgery. The development represents an important step in translating regenerative medicine advances into clinical practice in India.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard